TMCnet News
ImmusanT Data Shows Up-dosing Substantially Increases Nexvax2® Dose Levels That Are Safe and Tolerable, Further Supports Phase 2 StudiesImmusanT, Inc., a clinical-stage company developing Nexvax2®, a therapeutic vaccine designed to protect patients with celiac disease against exposure to gluten, and ultimately restore immune intolerance in celiac disease, today announced the publication of data demonstrating Nexvax2 to be both safe and tolerable at substantially higher dose levels when preceded by stepwise up-dosing from low starting doses. The manuscript, titled "Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study" was published online in EBioMedicine, an Open Access Elsevier journal supported by Cell Press and The Lancet. "This study demonstrates that gradually increasing the dose from a low, well-tolerated starting dose enables Nexvax2 to be safe and tolerable without dose-limiting adverse events at a level of 900 µg, six times the maximum tolerated dose with fixed dose schedules," said Robert Anderson, MBChB, Ph.D., Chief Scientific Officer of ImmusanT. "This is significant because dose strength is thought to determine the efficacy of peptide-based immunotherapy, and up-dosing now allows us to test efficacy of Nexvax2 at levels that have the potential to be more effective in patients inadvertently exposed to gluten while they do their best to maintain a gluten-free diet. These results support the potential use of Nexvax2 as a maintenance treatment for those living with celiac disease, and further support the advancement of Nexvax2 into phase 2 clinical trials." The results of this study met both primary and secondary endpoints, including no excess of adverse events and no increasing plasma cytokine levels after dosing. Self-reported gastrointestinal symptom scores were similar for treatment with Nexvax2 and placebo. The study findings provide clinical evidence supporting the interpretation that T-cell responsiveness to antigenic components of gluten in celiac disease is reduced by recent exposure to the same antigen. An important finding of the study was that regular administration of Nexvax2 over nine weeks including four weeks at the maintenance dose level of 900 µg had no damaging effect on the small intestine. Celiac disease patients homozygous for HLA-DQ2.5, a group that had been prone to first dose adverse events in previous trials of Nexvax2, were assessed in a separate cohort and had an adverse event profile afterhigh maintenance doses of Nexvax2 preceded by up-dosing similar to placebo. "Approximately 90% of celiac disease patients carry the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene, and at present the only solution for all those living on celiac disease is a gluten-free diet," said A. James M. Daveson, Faculty of Medicine at the University of Queensland and first author of the study. "This study marks the first clinical evidence of up-dosing in reducing adverse effects and in enabling higher maintenance dose levels in a T-cell mediated autoimmune disease. Dose optimization is a critical aspect of successful therapeutic development programs. The present study advances understanding of Nexvax2, which has the potential to provide a long-sought treatment option for celiac disease." "The significance of these results go beyond a safety and dosing study," said Leslie J. Williams, Chief Executive Officer of ImmusanT. "All outcome measures point to Nexvax2 not only being safe but active and tolerated without cytokine release at levels measurable in blood. We look forward to applying these insights to both our celiac disease program and other therapeutic programs going forward." To access the article, visit the Publications page of the ImmusanT website.
About Celiac Disease
About Nexvax2®
About ImmusanT, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005752/en/ |